Develops targeted therapeutics for the treatment of rare and underserved autoimmune and rare diseases.
Avalo Therapeutics, Inc., a pioneering clinical-stage precision medicine company headquartered in Rockville, Maryland, is dedicated to discovering, developing, and commercializing targeted therapeutics for patients facing unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. The company's innovative pipeline includes AVTX-002, a fully human anti-LIGHT monoclonal antibody currently in Phase II clinical trials. This therapeutic is being evaluated for its potential in treating non-eosinophilic asthma, inflammatory bowel disease (including moderate to severe Crohn's disease and ulcerative colitis), and is also undergoing Phase III trials for COVID-19 acute respiratory distress syndrome.
Avalo Therapeutics is also advancing AVTX-007, another promising candidate in its portfolio. AVTX-007 is a fully human anti-IL-18 monoclonal antibody currently undergoing Phase I clinical trials for conditions such as still's disease, which includes adult-onset still's disease and systemic juvenile idiopathic arthritis. Additionally, the company is making significant strides in rare genetic diseases with products like AVTX-801 and AVTX-803. AVTX-801, a D-galactose substrate replacement therapy, is in Phase III trials for phosphoglucomutase 1 deficiency (PGM1), known as PGM1-CDG. AVTX-803, a L-fucose substrate replacement therapy, is also in Phase III trials for LADII, also known as SLC35C1-CDG.
Originally known as Cerecor Inc., Avalo Therapeutics rebranded in August 2021 to reflect its strategic focus and expanded therapeutic portfolio. Founded in 2011, Avalo Therapeutics has rapidly emerged as a leader in precision medicine, leveraging its expertise in molecular targeting to advance therapies that have the potential to transform treatment outcomes for patients globally.